Updated: 8 hours ago
Medically reviewed by Dr Eric Wang- ChinaCureLink Team
Peking University Cancer Hospital, Fudan University Shanghai Cancer Center, and Tianjin Medical University Cancer Institute and Hospital are three TIL therapy centres in China worth investigating. Their relevance comes from specific clinical research—not proof that one is best for every cancer. If immunotherapy has stopped working, the key question is whether a centre has a suitable protocol for your exact diagnosis and can safely deliver the whole treatment pathway. Research participation and international-patient access need separate confirmation.
Key Takeaways |
• Choose by cancer subtype, product and protocol—not a general hospital ranking. • Chinese TIL programs include melanoma and cervical cancer research; results cannot be generalized to every solid tumor. • GC101’s developer reported marketing-application acceptance in October 2026; acceptance is not approval. • Tumor harvest, cell manufacturing and conditioning are part of treatment; serious complications can occur. • Confirm eligibility, recruitment, overseas acceptance and full costs before travel. |
Table of Contents
What TIL Therapy Involves
Tumor-infiltrating lymphocytes are immune cells found inside a tumor. In TIL therapy, a surgeon removes tumor tissue, a laboratory grows selected cells, and the cells are infused back into the patient. Many protocols use lymphodepleting chemotherapy beforehand and interleukin-2 (IL-2) afterward. The supporting treatment differs between products, so ask for the exact protocol.
TIL is different from CAR-T, CAR-NK and cancer vaccines. A cancer’s name alone does not establish eligibility. Melanoma subtype, previous treatment, available tumor tissue and fitness for conditioning matter. Patients with melanoma can also compare melanoma hospitals in China for standard treatment options.
What China’s TIL Research Actually Shows
The strongest recent development is the randomized phase II MIZAR-003 melanoma program, GC101 (nolgileucel) plus sintilimab versus chemotherapy, with estimated registry enrollment of 98. Its ASCO 2026 abstract describes lower-intensity conditioning and no IL-2 administration. In an October 23 sponsor report of ESMO follow-up, median progression-free survival was 4.37 versus 1.61 months, and response rates were 44.0% versus 8.2%. Overall-survival data were immature. Grade 3 or higher adverse events were mainly conditioning-related blood toxicities. These remain conference findings summarized by the developer, not a guarantee of benefit or low risk. [1–3]
On October 26, 2026, the developer reported acceptance of a Chinese marketing application for GC101 with sintilimab after at least two prior systemic treatments, including PD-1 therapy. Application acceptance does not establish marketing approval or routine overseas access. Verify the regulator’s current decision before making arrangements. [4]
For recurrent or metastatic cervical cancer, the GT101 phase I ASCO 2025 abstract reported responses in 5 of 11 treated patients (45.5%), including one complete response; median progression-free survival was 4.83 months at the August 2024 cutoff. Severe blood-count abnormalities and fever occurred with the treatment pathway. This small, uncontrolled conference study cannot establish a cure rate. A randomized phase II study, NCT06241781, now compares GT101 with gemcitabine. [5–6]
A separate four-patient Chinese investigator-initiated study of LM103 in advanced acral melanoma reported one complete response, two stable diseases and one progression. Its small size prevents reliable estimates of benefit or uncommon harms. The published individual response is described below. [7]
Three Documented TIL Centres to Compare
This is an evidence-based shortlist, not a numerical ranking. Selection reflects trial leadership, a named registry site or a published clinical program. General oncology rankings cannot establish TIL outcomes. Registry status below was checked on November 10, 2026; it does not confirm available places or acceptance of foreign patients.
Peking University Cancer Hospital & Institute — Beijing
Peking University Cancer Hospital’s melanoma team led the GC101 program reported at ASCO and ESMO 2026. The official hospital profile confirms a dedicated melanoma and sarcoma service. This makes it a relevant starting point for previously treated advanced melanoma, rather than a general recommendation for all solid cancers. [1–4,11]
Beijing · Grade 3A public cancer hospital Melanoma program · GC101 research · Randomized phase II Selection basis: GC101 melanoma trial leadership; no TIL outcome rank Known for: Leadership of the MIZAR-003 GC101 melanoma study. |
NCT06703398 was listed as recruiting in its August 5, 2026 update. The GC101 regimen differs from conventional high-dose IL-2-supported TIL therapy. Ask which protocol is actually available, whether the centre accepts overseas screening, and whether the current pathway is research or a subsequently approved indication.
Fudan University Shanghai Cancer Center — Shanghai
Fudan University Shanghai Cancer Center is listed as a recruiting location in NCT06241781, last updated November 9, 2026. This protocol addresses recurrent or metastatic cervical cancer, not every gynecologic tumor. [6,12]
Shanghai · Grade 3A public cancer hospital Cervical cancer trial · GT101 research · Multidisciplinary oncology Selection basis: named GT101 cervical cancer phase II site Known for: A recruiting site in the randomized GT101 cervical cancer study. |
Patients should compare the trial against their standard options through a cervical cancer team. The broader guide to cervical cancer hospitals in China can help frame that decision. The registry does not confirm an international-patient place or a particular clinician’s availability.
Tianjin Medical University Cancer Institute & Hospital — Tianjin
The GT101 phase II registry lists Tianjin Cancer Hospital as recruiting. Tianjin Medical University Cancer Institute and Hospital researchers also authored the four-patient LM103 acral melanoma study. These are distinct products and research settings; one does not establish access to the other. [6–8]
Tianjin · Grade 3A public cancer hospital GT101 cervical study · Acral melanoma research · Cancer research centre Selection basis: named GT101 site and published TIL research affiliation Known for: Documented involvement in cervical cancer TIL trials and melanoma translational research. |
Ask which service conducts screening, whether a melanoma or cervical cancer protocol matches the case, and where tumor harvest, manufacturing and inpatient care take place. The published LM103 affiliation alone does not establish an open commercial melanoma service.
China Versus International TIL Options
The United States granted accelerated approval to lifileucel (Amtagvi) in February 2024 for adults with unresectable or metastatic melanoma after PD-1 therapy and, when BRAF V600-positive, BRAF-targeted therapy with or without a MEK inhibitor. The FDA reported a 31.5% response rate in its 73-patient recommended-dose efficacy population. This is a defined approved indication, rather than permission to use every TIL product for every cancer. [9]
Do not compare that 31.5% directly with Chinese trial percentages. Products, conditioning, combinations, melanoma subtypes, prior treatment and study designs differ. GC101’s randomized comparison is against chemotherapy within its own trial; it does not establish superiority over lifileucel. For lung cancer, the separate guide to lung cancer TIL therapy in China explains a different research setting.
For international patients, an established local option may offer easier emergency care and follow-up. A Chinese trial may offer a relevant research pathway, especially when standard options are limited, but travel adds complexity. Compare the proposal with your home oncologist’s recommendations before committing.
Who May Qualify—and What Are the Risks?
For example, NCT06241781 requires recurrent or metastatic cervical cancer progressing after adequate first-line systemic therapy, age 18–70, ECOG performance status 0–1, adequate organ and marrow function, a removable lesion for manufacturing, and another measurable lesion. Its exclusions include important uncontrolled heart or lung disease and untreated central nervous system metastases. These are protocol-specific examples, not a personal eligibility assessment. [6]
The GC101 phase II record covers adults aged 18–75 with advanced melanoma excluding uveal melanoma, prior PD-1 failure and further treatment requirements. It also requires harvestable tumor tissue, a remaining measurable lesion and ECOG 0–1. Standard alternatives and biomarker-directed treatment must be reviewed first. [3]
The FDA’s lifileucel warning includes treatment-related death, prolonged severe low blood counts, severe infection, and heart, lung or kidney problems. This warning belongs to that product and regimen, but shows why a full TIL pathway needs experienced inpatient and emergency support. Ask about the proposed product’s own adverse events, conditioning, IL-2 use and intensive-care arrangements. Cell growth can fail or disease can worsen while waiting. [9–10]
Private Hospitals, Costs, and Overseas Access
For private hospitals such as Fuda, Modern, Concord or RoyalLee, this review did not verify an equivalent named TIL protocol with disease-specific eligibility and current overseas access. That is an evidence gap, not a judgment on all their services. A private-hospital package should be assessed using the same requirements as a public-centre proposal: exact product, study or approval identifier, treating team and safety support.
No verified all-inclusive international price was obtained for the shortlisted programs. Request separate figures for tumor surgery, pathology, manufacturing, conditioning, admission, infusion, IL-2 if used, infection treatment, intensive care, follow-up and repeat travel. Ask who pays if manufacturing fails or infusion is cancelled. The guide to cancer treatment costs in China provides budgeting context, not a TIL quote.
Three practical barriers deserve attention: translating pathology and prior treatments into the correct protocol; confirming recruitment and foreign-patient consent requirements; and arranging monitoring with the home oncologist. A recruiting registry entry alone resolves none of these. Read about clinical trials in China for foreigners before assuming enrollment is possible.
A personalized timeline must cover screening, surgery, laboratory manufacturing, reassessment, inpatient treatment and recovery. Do not book a short fixed stay based on infusion time alone. The guide to traveling to China for medical treatment is useful after medical suitability is confirmed.
Independent Guidance Before Booking
ChinaCureLink, a Medebound HEALTH company, represents patients rather than one hospital. Hospital and specialist matching is free. The team can organize pathology, biomarkers and prior treatments, identify potentially relevant programs, and help arrange a specialist video second opinion before travel. Video consultations are paid, with fees confirmed before booking.
The ChinaCureLink hospital matching process can compare up to three relevant hospitals and specialists. Neither facilitation nor an advisory call guarantees enrollment, a manufacturing slot or treatment success. On-site coordination has a separately quoted service fee when the patient proceeds.
Contacting Hospitals Directly vs. ChinaCureLink
Both routes can work. The treating hospital decides medical suitability; facilitation helps organize the assessment and practical arrangements.
Practical Next Steps Before Travel
1. Confirm the diagnosis and subtype. 2. Review standard alternatives and previous treatment. 3. Compare centres offering a relevant documented protocol. 4. Seek a specialist video opinion using the actual records. 5. Proceed only after eligibility, risks, full costs and follow-up are clear.
China’s melanoma and cervical cancer TIL programs offer credible research opportunities worth evaluating. The best centre is the one with a suitable, verifiable pathway and the capacity to support the entire treatment—not simply a recognizable name. Obtain individualized specialist guidance before traveling.
Get a Second Opinion
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
One Published Chinese Patient’s Complete Response
In Zhang and colleagues’ 2026 acral melanoma report, Patient 4 had recurrent plantar melanoma with lymph-node and skin lesions after PD-1 treatment. After LM103 TIL therapy, the authors described a partial response at six weeks and complete response at 12 weeks, with no recurrence reported at one year. The figure itself illustrates follow-up through 24 weeks. [7]
This was one patient in a four-patient research cohort. A complete response means no detectable disease by the study assessment; it does not prove cure. The report does not provide a sufficiently detailed safety table to estimate regimen toxicity. Individual results vary; a second opinion should assess eligibility and alternatives before travel. This is published research, not a ChinaCureLink client testimonial.
Figure 1 © Zhang et al., Advanced Science (2026), reproduced unaltered under CC BY 4.0. It presents the four-patient study and Patient 4’s imaging and clinical response; figure follow-up and narrative follow-up differ as described above. Primary source · CC BY 4.0
What Patients Say About ChinaCureLink & Medebound HEALTH
These are general experiences of care coordination, not evidence of TIL treatment outcomes.
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Frequently Asked Questions
Which Are the Best TIL Therapy Centres in China?
Three documented centres to investigate are Peking University Cancer Hospital for GC101 melanoma research, Fudan University Shanghai Cancer Center for the GT101 cervical cancer trial, and Tianjin Medical University Cancer Institute and Hospital for registered TIL research involvement. No verified head-to-head ranking establishes one as best for all cancers.
Is TIL Therapy Approved in China?
The programs discussed here require product-specific checks. GC101’s developer reported Chinese marketing-application acceptance on October 26, 2026; this is not approval. GT101 and LM103 evidence discussed here is clinical research. US approval of lifileucel does not authorize Chinese TIL products or guarantee overseas access.
Can Foreign Patients Join a Chinese TIL Trial?
Possibly, but recruitment status does not establish eligibility or acceptance. The hospital and sponsor must confirm the diagnosis, prior treatment, harvestable tumor, organ function, consent and follow-up requirements, available places and costs. Obtain written confirmation before travel.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
References
Peking exterior © N509FZ, 2022, CC BY-SA 4.0; displayed crop under the same license (source and license linked in References). Fudan and Tianjin photographs are authentic institutional images; editorial reuse permission requires confirmation before publication. Clinical Figure 1 © Zhang et al. 2026, CC BY 4.0, unaltered and scaled.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
You may also like:
